SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

USFDA completes inspection at Anuh Pharma’s facility

20 Sep 2019 Evaluate

The US Food and Drug Administration (USFDA) has successfully completed an inspection at Anuh Pharma’s facility. The facility was inspected by USFDA from September 16, 2019 to September 20, 2019. At the end of the inspection, no observation (483) was issued.  

Anuh Pharma is one of the leading manufacturers of Active Pharmaceutical Ingredients (APIs) and a leading importer, exporter, distributor and manufacturer of bulk drugs, chemicals and pharmaceutical formulations.

Anuh Pharma Share Price

84.15 1.20 (1.45%)
08-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1847.30
Dr. Reddys Lab 1293.25
Cipla 1347.70
Zydus Lifesciences 938.90
Lupin 2377.90
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×